Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
EXEMESTANE
TEVA CANADA LIMITED
L02BG06
EXEMESTANE
25MG
TABLET
EXEMESTANE 25MG
ORAL
30/100/500
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0141702001; AHFS:
APPROVED
2014-12-11
_____________________________________________________________________________________________ ACT EXEMESTANE (exemestane tablets) 25 mg Page 1 of 47 PRODUCT MONOGRAPH Pr ACT EXEMESTANE Exemestane Tablets, 25 mg Aromatase Inactivator; Anti-Tumour Agent Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Date of Revision: January 31, 2020 Submission Control No: 235333 _____________________________________________________________________________________________ ACT EXEMESTANE (exemestane tablets) 25 mg Page 2 of 47 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..................................................... 4 SUMMARY PRODUCT INFORMATION ................................................................... 4 INDICATIONS AND CLINICAL USE ........................................................................ 4 CONTRAINDICATIONS ............................................................................................ 4 WARNINGS AND PRECAUTIONS ............................................................................ 5 ADVERSE REACTIONS............................................................................................. 9 DRUG INTERACTIONS ............................................................................................16 DOSAGE AND ADMINISTRATION .........................................................................16 OVERDOSAGE .........................................................................................................17 ACTION AND CLINICAL PHARMACOLOGY.........................................................17 STORAGE AND STABILITY ....................................................................................20 DOSAGE FORMS, COMPOSITION AND PACKAGING ..........................................20 PART II: SCIENTIFIC INFORMATION .......................................................................... 21 PHARMACEUTICAL INFORMATION .....................................................................21 CLINICAL TRIALS . Կարդացեք ամբողջական փաստաթուղթը